Avedro, a Waltham, MA-based ophthalmic device and pharmaceutical company, completed a $25m Series C financing.
The round was led by SCP Vitalife and Aperture Venture Partners, with participation from existing investors Prism VentureWorks, De Novo Ventures, Flagship Ventures, Borealis Ventures and Echelon Ventures.
The company intends to use the capital to expand commercial operations of its systems outside the United States, and to seek US FDA clearance.
Led by David Muller, PhD, Avedro is developing systems and procedures for biomechanically strengthening and modifying the cornea
In conjunction with the funding, Jeff Dykan of SCP Vitalife, will join the company’s Board of Directors. Eric Sillman of Aperture Venture Partners will join as a Board Observer.